<DOC>
	<DOCNO>NCT00134017</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor bone marrow transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclophosphamide , mycophenolate mofetil , tacrolimus transplant may stop happen . PURPOSE : This clinical trial study well give combination chemotherapy together tacrolimus mycophenolate mofetil work treat patient undergo donor bone marrow transplant hematologic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy , Tacrolimus , Mycophenolate Mofetil Treating Patients Who Are Undergoing Donor Bone Marrow Transplant For Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine optimal dose post-transplant immunosuppression comprise high-dose cyclophosphamide , tacrolimus , mycophenolate mofetil administer myeloablative conditioning chemotherapy comprise busulfan cyclophosphamide follow allogeneic bone marrow transplantation patient high-risk hematologic malignancy . - Determine incidence severity acute graft-versus-host disease patient treat regimen . - Determine toxic effect regimen patient . Secondary - Determine immune reconstitution patient treat regimen . - Determine disease control patient treat regimen . OUTLINE : This pilot study . Patients stratify accord age ( ≤ 19 year old v &gt; 19 year old ) . - Myeloablative conditioning chemotherapy : Patients receive busulfan IV orally 4 time daily day -7 -4 OR day -6 -3 cyclophosphamide IV 1 hour daily day -3 -1 OR day -2 -1 . - Allogeneic bone marrow transplantation : Patients undergo allogeneic bone marrow transplantation day 0 . - Immunosuppression therapy : Patients receive 1 follow immunosuppressive treatment regimen : - Regimen 1 : Patients receive high-dose cyclophosphamide IV 1 hour day 3 . - Regimen 2 : Patients receive high-dose cyclophosphamide IV 1 hour day 3 4 . - Regimen 3 : Patients receive high-dose cyclophosphamide regimen 2 oral mycophenolate mofetil three time daily day 5-35 . - Regimen 4 : Patients receive high-dose cyclophosphamide regimen 2 mycophenolate mofetil regimen 3 . Patients also receive tacrolimus IV orally twice daily day 5-50 . After completion study transplantation , patient follow 30 60 day , 6 month , 1 year , annually thereafter . PROJECTED ACCRUAL : Approximately 30-60 patient ( approximately 5 per immunosuppressive treatment regimen ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Acute myeloid leukemia ( AML ) , meet 1 follow criterion : AML beyond first complete remission ( CR1 ) Refractory AML AML arise myelodysplastic syndrome ( MDS ) Secondary AML MDS Refractory anemia excess blast &gt; 10 % blast bone marrow Acute lymphoblastic leukemia ( ALL ) , meet 1 follow criterion : ALL CR1 1 follow highrisk feature : Philadelphia chromosome ( Ph ) positive disease Less 1 year age diagnosis Cytogenetic abnormality involve chromosome 11q23 ALL beyond CR1 Refractory ALL Chronic myeloid leukemia beyond first chronic phase Chronic myelomonocytic leukemia Chronic lymphocytic leukemia Stage IIIIV disease Does meet criterion bone marrow transplantation ( BMT ) study Myeloproliferative disorder Phnegative disease Hodgkin 's nonHodgkin 's lymphoma Chemotherapyresistant disease Paroxysmal nocturnal hemoglobinuria lifethreatening thrombosis Multiple myeloma Stage II III disease Very highrisk disease Having unrelated donor consider highrisk condition Meets medical criterion myeloablative BMT Sidney Kimmel Comprehensive Cancer Center Bone marrow donor available , meet 1 follow criterion : Genotypically HLAidentical sibling Phenotypically match firstdegree relative Unrelated donor molecularly match HLAA , B , C , DRB1 , DQB1 PATIENT CHARACTERISTICS : Age 6 month 65 year Performance status Not specify Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy No concurrent dexamethasone antiemetic immunosuppression therapy Radiotherapy Not specify Surgery Not specify Other No concurrent immunosuppressant ≥ 24 hour completion cyclophosphamide ( posttransplantation )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>